Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Sold by TrueMark Investments LLC

TrueMark Investments LLC lowered its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 3.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 37,765 shares of the company’s stock after selling 1,452 shares during the quarter. TrueMark Investments LLC’s holdings in Structure Therapeutics were worth $783,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. National Bank of Canada FI lifted its holdings in Structure Therapeutics by 1,448.2% in the first quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock valued at $51,000 after acquiring an additional 2,766 shares during the period. ANTIPODES PARTNERS Ltd lifted its holdings in Structure Therapeutics by 310.7% in the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company’s stock valued at $74,000 after acquiring an additional 3,213 shares during the period. Signaturefd LLC lifted its holdings in Structure Therapeutics by 6,550.0% in the second quarter. Signaturefd LLC now owns 6,650 shares of the company’s stock valued at $138,000 after acquiring an additional 6,550 shares during the period. GAMMA Investing LLC lifted its holdings in Structure Therapeutics by 663.8% in the first quarter. GAMMA Investing LLC now owns 8,776 shares of the company’s stock valued at $152,000 after acquiring an additional 7,627 shares during the period. Finally, Parallel Advisors LLC acquired a new stake in Structure Therapeutics in the second quarter valued at $171,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Trading Down 0.7%

Structure Therapeutics stock opened at $27.38 on Monday. The stock has a market cap of $1.58 billion, a PE ratio of -26.08 and a beta of -1.65. The stock has a 50-day moving average price of $22.99 and a 200 day moving average price of $21.66. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $13.22 and a 52 week high of $42.57.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08). On average, equities analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on GPCR shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, June 23rd. Guggenheim dropped their price target on Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. JMP Securities dropped their price target on Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating for the company in a research report on Thursday, August 7th. Lifesci Capital upgraded Structure Therapeutics to a “strong-buy” rating in a research report on Monday, September 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Structure Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $68.67.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.